TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21184977

Group type: EXPERIMENTAL
Intervention: Hindi version of the Quality of Life for Eating Disorders questionnaire (QOL ED‐H)
Number of subjects: 95

Group type: COMPARATOR
Intervention: English version of the Quality of Life for Eating Disorders questionnaire (QOL ED)
Number of subjects: 95
Study: 19299777

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg tablet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 40
Study: 17719327

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol/kg/min) as a continuous infusion beginning 12 hours before CABG and continuing for 48 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard therapy at the discretion of the surgeon
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol/kg/min) as a continuous infusion
Number of subjects: 20
Study: 14744921

Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg twice daily for 4 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: celecoxib 200 mg/d for 4 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg twice daily at peak
Number of subjects: 25

Group type: COMPARATOR
Intervention: celecoxib 200 mg/d at peak
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg twice daily for 24 hours
Number of subjects: 25

Group type: COMPARATOR
Intervention: celecoxib 200 mg/d for 24 hours
Number of subjects: 25
Study: 11799264

Group type: EXPERIMENTAL
Intervention: Increased dialysis treatment time by 2 h and reduced dry weight (group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Increased dialysis treatment time by 2 h without changing dry weight (group 2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Reduced dry weight without changing dialysis treatment time (group 3)
Number of subjects: 21
Study: 9713730

Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl/pancuronium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam/halothane/fentanyl/pancuronium
Number of subjects: 20
Study: 7975783

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2a (IFN alpha-2a) at a dosage of 3 x 3 million units per week for 1 year
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2a (IFN alpha-2a)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dosis escalation after 8 and 16 weeks in serological non-responders
Number of subjects: 40
Study: 2596943

Group type: EXPERIMENTAL
Intervention: Minimal intervention strategy (monthly mailed informational packets and monthly to quarterly telephone contacts)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 90
Study: 1122924

Group type: EXPERIMENTAL
Intervention: Fat emulsion infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prolonged exercise
Number of subjects: 12
Study: 31550947

Group type: EXPERIMENTAL
Intervention: APT Triathlon PS TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: MBT Triathlon PS TKA
Number of subjects: 60
Study: 28118788

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic HH repair
Number of subjects: 36

Group type: COMPARATOR
Intervention: 2D laparoscopic HH repair
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic HH repair with mesh positioning
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic HH repair without mesh positioning
Number of subjects: 36

Group type: COMPARATOR
Intervention: 2D laparoscopic HH repair with mesh positioning
Number of subjects: 36
Study: 26167618

Group type: EXPERIMENTAL
Intervention: ART within 4 weeks of starting TB treatment (Arm-1)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: ART after the intensive phase of TB treatment (Arm-2)
Number of subjects: 642

Group type: COMPARATOR
Intervention: ART after completing TB treatment (Arm-3)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Comparison between Arm-1 and Arm-2
Number of subjects: 642

Group type: COMPARATOR
Intervention: Comparison between Arm-3 and Arm-2
Number of subjects: 642
Study: 22886805

Group type: EXPERIMENTAL
Intervention: Computer-navigated MIS anterior approach
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional posterolateral approach
Number of subjects: 75
Study: 21301346

Group type: EXPERIMENTAL
Intervention: lotrafilcon A (Dk, 140)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: balafilcon A (Dk, 91)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: galyfilcon A (Dk, 60)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: senofilcon A (Dk, 103)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control eye (no lens)
Number of subjects: 29
Study: 19602507

Group type: EXPERIMENTAL
Intervention: Superficial vein surgery and compression
Number of subjects: 500

Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 500
Study: 16728248

Group type: EXPERIMENTAL
Intervention: Ultrasound activation with EDTA irrigation for 30 seconds before etching procedure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group treated using the etching procedure
Number of subjects: 24
Study: 15374576

Group type: EXPERIMENTAL
Intervention: Disease states derived from PANSS scores
Number of subjects: 663
Study: 11194687

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 micrograms)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intracervical dinoprostone gel
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 61
Study: 9562232

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MPA) 2 x 1 g/day during peritoneal dialysis
Number of subjects: 5

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MPA) 2 x 1 g/day without peritoneal dialysis
Number of subjects: 5
Study: 8201376

Group type: EXPERIMENTAL
Intervention: Brachytherapy (BRT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No Brachytherapy (no-BRT)
Number of subjects: 45
Study: 2440455

Group type: EXPERIMENTAL
Intervention: 2.5 mg midodrin hydrochloride administered intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2.5 mg midodrin hydrochloride as drinking solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2.5 mg midodrin hydrochloride as tablet (Gutron)
Number of subjects: 12
Study: 29649996

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study: 27034316

Group type: EXPERIMENTAL
Intervention: Twinky Star Flow (Voco, Cuxhaven, Germany)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dyract Flow (Dentsply, Konstanz, Germany)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: R&D Series Nova Compomer Flow (Imicryl, Konya, Turkey)
Number of subjects: 30
Study: 24860256

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg kg(‐1), remifentanil 0.30 μg kg min(‐1), and sevoflurane 1.0 MAC
Number of subjects: 83

Group type: COMPARATOR
Intervention: Propofol 1.5 mg kg(‐1), remifentanil 0.30 μg kg min(‐1), and rocuronium 0.45 mg kg(‐1)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups (SEVO and MR)
Number of subjects: 83
Study: 22863096

Group type: EXPERIMENTAL
Intervention: Probiotic cheese containing Lactobacillus plantarum Tensia at a concentration of 9.6 log cfu/g for 30 consecutive days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic cheese with a daily dose of 10.3 or 8.17 log cfu/serving for 3 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular semihard Edam-type cheese with probiotic additive at a daily dose of 50g or in excess (100g) and with a probiotic daily dose of 10 log cfu for 3 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic cheese consumption confirmed presence of the ingested probiotic strain in feces.
Number of subjects: 0
Study: 20139430

Group type: EXPERIMENTAL
Intervention: Quinagolide 50 microg/day
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Quinagolide 100 microg/day
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Quinagolide 200 microg/day
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: All quinagolide groups combined
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Quinagolide
Number of subjects: 182
Study: 18672532

Group type: EXPERIMENTAL
Intervention: Intermittent therapy (8-week on/8-week off)
Number of subjects: 86
Study: 15903385

Group type: EXPERIMENTAL
Intervention: 30‐minute lower‐body stretching protocol (S)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3 sets of a leg press exercise using 90% of the subjects' previously determined 1 repetition maximum (P)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10 minutes of quiet sitting (C)
Number of subjects: 10
Study: 14625133

Group type: EXPERIMENTAL
Intervention: Insulin lispro mixture (25% insulin lispro and 75% NPL) plus metformin (Mix25+M)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Glibenclamide plus metformin (G+M)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Insulin lispro mixture (Mix25+M)
Number of subjects: 597
Study: 11106203

Group type: EXPERIMENTAL
Intervention: Chlorine exposure at 0.5 ppm
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control exposure at 0 ppm
Number of subjects: 7
Study: 9485980

Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 2% propofol
Number of subjects: 110
Study: 8370356

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (nisoldipine) administered before or during ischaemia
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study: 3523396

Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meperidine (150 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluradoline (450 mg)
Number of subjects: 20
Study: 29436172

Group type: EXPERIMENTAL
Intervention: 100 mg/wk testosterone cypionate
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 250 mg/wk testosterone cypionate
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 500 mg/wk testosterone cypionate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 31
Study: 27510295

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1 mg/kg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 100% normobaric oxygen with mask, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen
Number of subjects: 90
Study: 24341963

Group type: EXPERIMENTAL
Intervention: Folder support intervention
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Web-based support intervention
Number of subjects: 241
Study: 24251744

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) for 360 s at 30 Hz and 4 mm peak‐to‐peak displacement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham position (CON)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV)
Number of subjects: 30
Study: 20846257

Group type: EXPERIMENTAL
Intervention: Oral 600 µg misoprostol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sublingual 600 µg misoprostol
Number of subjects: 64
Study: 18201934

Group type: EXPERIMENTAL
Intervention: KADIAN (morphine sulfate extended-release) with 240 mL 40% alcohol
Number of subjects: 32

Group type: COMPARATOR
Intervention: KADIAN (morphine sulfate extended-release) with water (fasted)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: KADIAN (morphine sulfate extended-release) with alcohol under fasted or fed conditions
Number of subjects: 32
Study: 16620710

Group type: EXPERIMENTAL
Intervention: Preoperative hepatic and regional arterial infusion chemotherapy (PHRAIC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (radical surgery and general venous chemotherapy)
Number of subjects: 110
Study: 12791624

Group type: EXPERIMENTAL
Intervention: Aglycone form of isoflavones (daidzein and genistein)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucoside form of isoflavones (daidzein and genistein)
Number of subjects: 15
Study: 10967371

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily) + Folic Acid (500 microg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily) + Placebo
Number of subjects: 127
Study: 8641579

Group type: EXPERIMENTAL
Intervention: C-ROPM program
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7 + 3 + vincristine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7 + 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More intensive chemotherapy during remission induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Number of subjects: 0
Study: 31549217

Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6 (mFOLFOX6)
Number of subjects: 864
Study: 29385446

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Canada (general population)
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: USA (general population)
Number of subjects: 2016
Study: 27068574

Group type: EXPERIMENTAL
Intervention: Classroom-based physical activity program (9-month duration, integrated into math lessons)
Number of subjects: 505
Study: 24520671

Group type: EXPERIMENTAL
Intervention: Transurethral bipolar plasmakinetic enucleation and resection of the prostate (PKERP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Transurethral bipolar plasmakinetic resection of the prostate (PKRP)
Number of subjects: 180
Study: 22992267

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 900 mg capsules thrice daily (total daily dose 2.7 g per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules thrice daily
Number of subjects: 0
Study: 18358737

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² administered every 21 days
Number of subjects: 764
Study: 16192735

Group type: EXPERIMENTAL
Intervention: Intranasal 17beta‐estradiol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Oral estrogens
Number of subjects: 29
Study: 14673604

Group type: EXPERIMENTAL
Intervention: Carrot meal (188 g carrot purée providing 30 mg beta-carotene)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tomato meal (61 g tomato purée providing 30 mg lycopene)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Spinach meal (260 g cooked chopped spinach providing 30 mg lutein)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Carrot meal
Number of subjects: 16
Study: 10601560

Group type: EXPERIMENTAL
Intervention: CEOP-B/VIMB
Number of subjects: 129

Group type: COMPARATOR
Intervention: ProMACE-CytaBOM
Number of subjects: 129
Study: 9342767

Group type: EXPERIMENTAL
Intervention: 900 mg of hypericum extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bright light therapy combined with hypericum
Number of subjects: 0
Study: 8474513

Group type: EXPERIMENTAL
Intervention: Annual screening for colorectal cancer
Number of subjects: 46551

Group type: EXPERIMENTAL
Intervention: Biennial screening for colorectal cancer
Number of subjects: 46551

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 46551
Study: 3513670

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OB) 40 to 400 micrograms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OB) 100 to 400 micrograms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OB) 20 to 400 micrograms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OB) 100 and 400 micrograms
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isoproterenol (ISO) 150 micrograms
Number of subjects: 14
Study: 31781946

Group type: EXPERIMENTAL
Intervention: Oncologists' estimates of expected survival time (EST)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Patients' estimates of their most-likely survival scenario
Number of subjects: 179
Study: 30297565

Group type: EXPERIMENTAL
Intervention: Phosphoric acid etched
Number of subjects: 48

Group type: COMPARATOR
Intervention: ER: YAG laser etched
Number of subjects: 48

Group type: COMPARATOR
Intervention: Phosphoric acid plus ER: YAG laser etched
Number of subjects: 48
Study: 26946332

Group type: EXPERIMENTAL
Intervention: c‐tDCSUHCDS of M1‐DLPFC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: c‐tDCSUHCDS of M1‐V1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham c‐tDCSUHCDS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: c‐tDCS of M1 and V1
Number of subjects: 12
Study: 24932989

Group type: EXPERIMENTAL
Intervention: Crystalens AO
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ReSTOR +3.0
Number of subjects: 78

Group type: COMPARATOR
Intervention: Tecnis Multifocal
Number of subjects: 78
Study: 23767178

Group type: EXPERIMENTAL
Intervention: Women with breast cancer (study group)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Women with secure attachment (regardless of breast cancer status)
Number of subjects: 240
Study: 20118124

Group type: EXPERIMENTAL
Intervention: Hand elevation postoperatively
Number of subjects: 113

Group type: COMPARATOR
Intervention: No hand elevation (Control)
Number of subjects: 113
Study: 18359127

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (0.03% or 0.1%)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 197
Study: 17285971

Group type: EXPERIMENTAL
Intervention: Ephedrine Test
Number of subjects: 0
Study: 14600693

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine rinse
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1% NaOCl as irrigant (Control)
Number of subjects: 24
Study: 11127348

Group type: EXPERIMENTAL
Intervention: Academic detailing intervention on universal precautions education
Number of subjects: 55
Study: 8678347

Group type: EXPERIMENTAL
Intervention: Prophylaxis using a 13,500 ppm fluoridated pumice
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prophylaxis with pumice followed by application of a 2500 ppm fluoridated paste
Number of subjects: 36

Group type: COMPARATOR
Intervention: Prophylaxis with pumice only (Control)
Number of subjects: 36
Study: 1469927

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg twice daily for 10 days)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily for 10 days)
Number of subjects: 203
Study: 6362693

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 24
Study: 31303349

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6417
Study: 29457271

Group type: EXPERIMENTAL
Intervention: Ambient artificial tears (aAT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Refrigerated artificial tears (rAT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Morning instillation of artificial tears
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Evening instillation of artificial tears
Number of subjects: 18
Study: 26954560

Group type: EXPERIMENTAL
Intervention: Flapless surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open flap surgery (traditional surgery)
Number of subjects: 40
Study: 23647918

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 30
Study: 23517838

Group type: EXPERIMENTAL
Intervention: Fentanyl and midazolam during the procedure
Number of subjects: 2013

Group type: COMPARATOR
Intervention: No treatment (control subjects)
Number of subjects: 2013
Study: 20682932

Group type: EXPERIMENTAL
Intervention: Therapist intervention
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Computer intervention
Number of subjects: 726

Group type: COMPARATOR
Intervention: Control (brochure)
Number of subjects: 726
Study: 19034108

Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine, 0.25% (TEA group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10 ml saline (control group)
Number of subjects: 24
Study: 16636722

Group type: EXPERIMENTAL
Intervention: 0.18% isotretinoin
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.05% isotretinoin
Number of subjects: 40
Study: 12716237

Group type: EXPERIMENTAL
Intervention: On-site collaborative care intervention (N = 57), including education, 2 visits, follow-up phone calls, and paroxetine
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual care by primary care physician (N = 58)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 115
Study: 10728741

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF)
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 1839

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1839
Study: 9124833

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg biweekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg biweekly with Rifampin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dapsone 100 mg biweekly without Rifampin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapsone with high bilirubin levels (> 1.2 mg/dl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapsone with normal bilirubin levels (0.7 mg/dl)
Number of subjects: 0
Study: 1559334

Group type: EXPERIMENTAL
Intervention: Oral administration of contraceptive tablet (0.25 mg LNG, 0.05 mg ethinylestradiol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vaginal administration of contraceptive tablet (0.25 mg LNG, 0.05 mg ethinylestradiol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups (oral and vaginal)
Number of subjects: 10
Study: 3989400

Group type: EXPERIMENTAL
Intervention: Palpatory findings on the cervical spine by three different chiropractors
Number of subjects: 40
Study: 30345939

Group type: EXPERIMENTAL
Intervention: Nutrition education curriculum (implemented twice per week for 6 weeks)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 131